Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Authors:

Abstract
Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Funding Information
  • National Natural Science Foundation of China (No. 81170016, No. 81170787, No. 81200022, No. 81200023, No. 81270067, No. 31571493, No. 81571928)
  • Natural Science Foundation of Zhejiang Province (LY13H150002, LY12H16005)

This publication has 96 references indexed in Scilit: